key: cord-0737297-63mee3hy
authors: Hamadé, Amer; Jambert, Lucas; Tousch, Jonathan; Talbot, Marjolaine; Dervieux, Benjamin; Nazer, Tarek EL.; Bensalah, Naouel; Michel, Pierre; Lehn-Hogg, Michèle; Buschenrieder, Nathalie; Obringer, Golnaz; Jacquemin, Laurent; Hinschberger, Olivier; Stephan, Dominique; Woehl, Bastien
title: Systematic Duplex Ultrasound Screening in Conventional Units for COVID-19 Patients with Follow-up of 5 Days
date: 2020-12-02
journal: J Vasc Surg Venous Lymphat Disord
DOI: 10.1016/j.jvsv.2020.11.019
sha: 50940babe0ee87db00d81b5ac69e035cde924582
doc_id: 737297
cord_uid: 63mee3hy

OBJECTIVE: COVID-19 patients may develop coagulopathy which is associated with poor prognosis and high risk of thrombosis. The objective of this work was to evaluate the prevalence of deep venous thrombosis of lower limbs (DVT) through ultrasonography in patients infected with COVID-19 admitted to hospital in conventional units with 5 days monitoring. The secondary objective was to determine if D-dimer levels body mass index (BMI) and C-reactive ; protein (CRP) were associated with DVT. MATERIALS AND METHODS: 72 patients with a mean age of 65±12.3 years infected with COVID-19 were admitted to three conventional units at our institution ,28 patients were women. A COVID-19 diagnosis was made by transcriptase polymerase chain reaction by means of nasopharyngeal swab or by chest computer tomography (CT) without iodine contrast media. Demographics ,co-morbidities characteristics and laboratory parameters were collected . A preventive anticoagulation treatment was established on admission with low molecular weight heparin (LMWH) . A complete venous duplex ultrasound (DU) test of lower limbs was performed on Day (D) 0 and D5 .A pulmonary CT angiograms with iodine contrast media (CTPA) was required when was ; suspected pulmonary embolism (PE). RESULTS: On D0 the DU showed acute DVT in seven patients (9.75%).A CTPA was performed in 12 patients (16.65%) ,3 of whom with an acute PE (25 %). On D0 acute DVT was not significantly associated with CRP (mean 101±98.6 in the group without DVT versus 67.6±58.4 mg/l p=0.43) or BMI ( 27.7 ±5.04 versus 28.1 ± 2.65 Kg/m2 p=0.54 ).However we found a significant association between acute DVT and D-dimer levels (1536±2347 versus 9652 ±10205 ng/ml p <0.01).Among the patients included on D0 only 32 had a DU on D5.Forty of them (55.55%) were not examined for the following reasons : 7 were previously diagnosed with VTE on D0 (9.7%) and therefore had been excluded on D5 8 (11%) had been transferred to the intensive care unit (ICU) 10 (14%) discharged from the hospital 5 (7%) died and 10 ( 13.9%) due to technical issues. On D5 5 patients had acute DVT (15.6%) in addition to those found on D0 3 were distal and 2 proximal despite preventive anticoagulation with LMWH. CONCLUSIONS: Hospitalized non ICU patients with COVID-19 pneumonia have a high frequency of venous thrombotic events justifying screening with duplex ultrasound.

This work is an observational study , therefore no power calculations were 10 used. Qualitative and quantitative variables were analyzed using means or 11 medians , percentages and standard deviations. we observed 13 patients (18%) with VTE events , 12 of of them (16.7%) with acute DVT.

The prevalence was significant mainly on D5(15.6% ) despite anti-thrombotic prophylaxis.

14 Obesity appears to be associated with an increased risk of VTE in general patients were treated with preventive and therapeutic LMWH. 

The Outbreak of COVID-19 18 in Mulhouse, : Hospital Crisis Management and Deployment of Military Hospital 19

During the Outbreak of COVID-19 in Mulhouse, France. Ann Intensive Care

CORRESPONDING AUTHOR RESPONSIBILITY. The corresponding author confirms that they and the co-authors have read and agreed to follow the policies of the Journal of Vascular Surgery Publications. The corresponding author also confirms that they and the co-authors have approved the manuscript files, disclosed all relevant conflicts of interest, and verified their contributions and conflicts on this form prior to submission. The corresponding author is responsible for serving these same functions for the revision and resubmission of this work.

Please include the names of the corresponding author and the post-publication corresponding author on the title page of the manuscript.

☒ COMPLETELY ORIGINAL. The authors certify that this manuscript is original, has been written by the stated authors, has not been published previously, and is not under consideration for publication by another journal. ☐ FOLLOW UP. This work is a follow up from a previously published study. It contains a patient cohort that has been reported previously. table to indicate their involvement in the creation of this manuscript. It is important that a box is checked in each authorship category, otherwise the person will not qualify for authorship and the manuscript will be returned to the authors for correction.The boxes for "Approval" and Accountability" must be checked for ALL authors. If an author declines to approve or be accountable for the work, they may not be included as authors.CRITERIA REQUIRED FOR AUTHORSHIP. Authors must have contributed in all four categories. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

List 2 initials for each author (example: AS, BP).In the case of two authors with the same initials, please use their middle initial to differentiate between them (example: JEB, JTB). 

You may add more rows if needed.Overall responsibility. Click or tap here to enter text. assumes overall responsibility and guarantees the scientific integrity of the work as a whole.

☐ ☐ ☐ ☐ SHARED FIRST AUTHORSHIP: Check this box if two authors participated equally and should share "first authorship".List these as first and second authors.

If two authors participated equally and should share "senior authorship" enter their initials here:

EACH author must disclose all relevant financial and nonfinancial potential conflicts of interest with respect to this manuscript. Potential conflicts of interest include, but are not limited to:1. A financial contribution to the author or the authors' institution from a company or organization that might benefit (or lose) financially from the results, conclusions or discussion presented in the manuscript Examples include: Royalties, Patents (or patents pending), fees for consulting, fees for speaking when organized by a corporate sponsored speakers' bureau, funds for a member of the author's staff or family 2. Ownership of stocks, shares or options in a company or organization that might benefit (or lose) financially from the results, conclusion or discussion presented in the paper/letter 3. A commercial interest in the form of a relationship with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients 4. Other potential conflicts include: a. an academic association or antagonism with someone whose interest might be affected by the paper b. membership in a special interest group whose interests might be affected by the paper c. other strong convictions that might have affected what was written List conflicts of interest for EACH author below. If there are no conflicts of interest, please state "The authors have no competing interests" in the space below.

Each author must disclose the name and involvement of all entities that provided financial support for this work. Please list the funding (grant, scholarships, donated devices, etc.) and describe the involvement of each sponsor in the: 1. Study design; collection, analysis, and interpretation of data; 2. Manuscript writing 3. The decision to submit the manuscript for publication 4. Any other involvement in the creation of the manuscript (Artwork, critical revision, etc.)

The authors must make a meaningful disclosure regarding their discussions of off label or unapproved drugs or devices.☐ This study does include off label drugs and/or devices.The specific names of the products discussed are: Click or tap here to enter text.☒ This study does not include off label drugs and/or devices.

Example:This work was funded by corporation XYZ. Corporation XYZ had no involvement in the study design or collection, analysis, and interpretation of data. Corporation XYZ paid for a professional editor to assist with writing the manuscript. Corporation XYZ was not involved in the decision to submit the manuscript for publication.

The corresponding author confirms that they and the co-authors believe that this form and all accompanying files describe truthful facts. The corresponding author also certifies that they and each co-author have participated to a sufficient degree to take public responsibility for this manuscript, that their contributions and relevant conflicts of interest are accurately and completely reported on this form.